SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Uprosertib

Item No. 19904

CAS Registry No.:	1047634-65-0
Formal Name:	N-[(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide
Synonyms:	GSK795, GSK2141795
MF:	$C_{18}H_{16}Cl_2F_2N_4O_2$
FW:	429.2
Purity:	≥98%
UV/Vis.:	λ_{max}: 239 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

Uprosertib is supplied as a crystalline solid. A stock solution may be made by dissolving the uprosertib in the solvent of choice. Uprosertib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of uprosertib in these solvents is approximately 1 mg/ml.

Uprosertib is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

Description

Uprosertib is a selective, orally bioavailable inhibitor of Akt (IC_{50}s = 180, 328, and 38 nM for Akt1, Akt2, and Akt3, respectively).[1] Uprosertib preferentially inhibits the proliferation of human cancer cell lines with Akt pathway activation *via PI3K/PTEN* mutation or loss.[2] It can cause cell cycle arrest and consequent tumor growth inhibition in mice bearing either BT474 breast tumor or SK-OV-3 ovarian tumor xenografts.[2]

References

1. Pachl, F., Plattner, P., Ruprecht, B., *et al*. Characterization of a chemical affinity probe targeting Akt kinases *J. Proteome Res*. **12(8)**, 3792-3800 (2013).
2. Dumble, M., Crouthamel, M.-C., Zhang, S.-Y., *et al*. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. *PLoS One* **9(6)**, (2014).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM